Pharmacy Webinar 43
From Autoimmune Disease to Depression to Cancer, Oh My!:
The Latest Evidence-Based Research on the Many Uses of LDN
with Peter Koshland, PharmD
TUESDAY, October 16, 2018: 6:30 pm - 8:30 pm
2 CEs (pending approval by OBNM)
*Please note this webinar is pending approval for 2 pharmacy CEs
2 CEs for CA acupuncturists (pending)
REGISTER NOW * $75 members | $95 non-members
Category 1 TM Credits
CE Provider #805
310 670 8100
This course is pending approval by The California Acupuncture Board for 2 hours of continuing education
This course will be available as a self study after the date of the live webinar.
*Refunds not available
This webinar is an updated look at Low-Dose Naltrexone (LDN); a treatment that has potentially relevant application of any disease that involves inflammation or immune dysregulation. LDN has such broad therapeutic applicability that it’s easy to be intimidated of or confused by how best to utilize it. From autoimmune disease to depression to cancer therapy, a large amount of new research about this therapy has emerged in the last few years. This research has challenged conventional wisdom on how to successfully utilize LDN, including the best way to dose it and what to do if a patient does not respond. This webinar will provide an updated, evidence-based review of the many uses of LDN.
Attend this presentation to confidently:
2. What patients are good candidates for LDN.
3. How to dose and monitor patients on LDN.
4. What are potential adverse reactions.
5. What to do if a patient does not respond to LDN.
Peter Koshland, PharmD is a graduate of Georgetown University and the UCSF School of Pharmacy. He started out his pharmacy career working in independent community pharmacies, including Elephant Pharm, a Bay Area pharmacy that integrated Eastern and Western medicine. As Director of Pharmacy at Elephant Pharm, he grew the compounding service and introduced its benefits to numerous local doctors and patients.
In 2009, Peter opened Koshland Pharm: Custom Compounding Pharmacy in order to further the availability of customized medications to patients in the Bay Area and across the State of California. Since its opening, Koshland Pharm has achieved multiple distinctions under Peter’s leadership as CEO and head pharmacist.
In addition to his current CEO role at Koshland Pharm, Peter is an Adjunct Clinical Professor of Pharmacy at UCSF, introducing pharmacy students to compounding. He also trains and consults with doctors across the state in the areas of hormone replacement, thyroid disorders and compounding applications for a variety of medical disciplines. In 2013, he received the Innovative Pharmacist of the Year award from the California Pharmacists Association, as well as the Outstanding Young Compounding Pharmacist of the Year from the Professional Compounding Centers of America.